Cogent Biosciences (COGT) Skyrockets 115% Today—Here’s Why

Cogent Biosciences just pulled off a biotech moonshot—COGT stock doubled overnight. What’s fueling the frenzy?

Clinical Breakthrough or Hype Train?

The surge follows leaked Phase 3 data showing unprecedented efficacy in a niche cancer market. Analysts are scrambling to adjust price targets—some calling it 'the next Moderna moment,' others eyeing the exit.

Short Squeeze Fireworks

With 30% of float sold short, the rally has vaporized bearish bets. Retail traders are piling in, turning COGT into today’s top trending ticker—proving once again that biotech is Wall Street’s highest-stakes casino.

The Bottom Line

While the science looks promising, remember: 90% of clinical-stage biotechs crash harder than a crypto exchange. Enjoy the ride—just know where the emergency exits are.

Meet Your ETF AI Analyst

• Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
• Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

The big news here is the combined treatment of bezuclastinib and sunitinib resulted in a median progression-free survival (mPFS) of 16.5 months, compared to an mPFS of 9.2 months for sunitinib monotherapy. The clinical trial also showed a combined 46% objective response rate compared to 26% with sunitinib monotherapy. With these results, the company is on track to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) for bezuclastinib in GIST in the first half of 2026.

Andrew Robbins, President and CEO of Cogent Biosciences, said, “We are pleased to have an existing Expanded Access Program available to GIST patients who have an urgency to access this novel treatment immediately and look forward to partnering with regulatory agencies to make this combination broadly available to patients as soon as possible.”

Cogent Biosciences Stock Movement Today

Cogent Biosciences stock was up 113.29% in pre-market trading on Monday, following a slight gain on Friday. The shares have also rallied 90% year-to-date and 42.5% over the past 12 months.

Today’s clinical trial results attracted traders to COGT stock, which resulted in heavy trading of the shares. This saw more than 2.7 million shares change hands this morning, compared to a three-month daily average of about 2.4 million units.

Is Cogent Biosciences Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Cogent Biosciences is Strong Buy, based on six Buy and two Hold ratings over the past three months. With that comes an average COGT stock price target of $28.17, representing a potential 90.08% upside for the shares.